Get the Stockscreener App
46.74
0.47%
0.22
Pre-market:
45.51
-1.23
-2.63%
Tarsus Pharmaceuticals Inc stock is traded at $46.74, with a volume of 536.62K.
It is up +0.47% in the last 24 hours and down -11.66% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$46.52
Open:
$46.96
24h Volume:
536.62K
Relative Volume:
0.75
Market Cap:
$1.79B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-10.07
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+5.44%
1M Performance:
-11.66%
6M Performance:
+72.86%
1Y Performance:
+99.06%
1-Day Range:
$45.72
$48.00
1-Week Range:
$44.40
$48.00
52-Week Range:
$20.08
$57.14
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
46.74 | 1.79B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus PharmaceuticalEye Care Therapeutics - MSN
Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair - MSN
Grant GrossMendelsohn LLC Sells 14,331 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Average Target Price from Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Publishes Corporate Presentation – Enhances Stakeholder InsightOn January 13, 2025, Tarsus Pharmaceuticals, Inc. shared its corporate presentation on its website’s Investor & News section, as detailed in the lates - Defense World
Tarsus Pharmaceuticals, Inc Announces Board and Committee Changes -January 17, 2025 at 05:09 pm EST - Marketscreener.com
Midday Stock Roundup: Shares of Boot Barn Shoot Up - Orange County Business Journal
Assenagon Asset Management S.A. Buys 5,565 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 6.3%Time to Sell? - MarketBeat
Tarsus Pharmaceuticals is Now Oversold (TARS) - Nasdaq
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround - Yahoo Finance
Tarsus CEO Bobby Azamian: Clearing Crusty Eyelids with Xdemvy - Orange County Business Journal
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap DownTime to Sell? - MarketBeat
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY - WICZ
Tarsus Provides 2025 Update: Accelerating the Launch of - GlobeNewswire
Tarsus' XDEMVY Eye Treatment Hits $113M Sales, Plans New Rosacea Drug Development - StockTitan
Analysts Expect Breakeven For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Before Long - Simply Wall St
JPMorgan Chase & Co. Has $14.48 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
JPMorgan Chase & Co. Buys 420,057 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength? - Yahoo Finance
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Franklin Resources Inc. - Defense World
Tarsus Pharmaceuticals stock soars to 52-week high of $56.84 By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month HighHere's What Happened - MarketBeat
Tarsus Pharmaceuticals stock soars to 52-week high of $56.84 - Investing.com
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run - MSN
Geode Capital Management LLC Increases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Geode Capital Management LLC Purchases 62,555 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex - Yahoo Finance
Comparing Tarsus Pharmaceuticals (NASDAQ:TARS) and CG Oncology (NASDAQ:CGON) - Defense World
Barclays PLC Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Barclays PLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World
State Street Corp Sells 26,260 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Fmr LLC Buys 3,537 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by State Street Corp - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week HighHere's What Happened - MarketBeat
When the Price of (TARS) Talks, People Listen - Stock Traders Daily
Tarsus Pharmaceuticals: Worthy Of A Small Bet (NASDAQ:TARS)🤭 Experimente a diversão no C333Bet - Oficjalny Portal Gminy Brzesko
Wellington Management Group LLP Acquires 18,019 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals: Worthy Of A Small Bet (NASDAQ:TARS❌ Ilumine seu dia com Estrela BRT - Oficjalny Portal Gminy Brzesko
Tarsus Pharmaceuticals Insider Lowered Holding By 16% During Last Year - Simply Wall St
Lord Abbett & CO. LLC Acquires 131,636 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
Tarsus Pharmaceuticals' SWOT analysis: eye care stock's growth trajectory By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals' SWOT analysis: eye care stock's growth trajectory - Investing.com
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):